GSK acquired global rights to Brexafemme, a novel antifungal from Scynexis that is approved for treating vaginal yeast infections. The deal also gives GSK the chance to commercialize the drug in other indications.
Organon’s proposed acquisition of Forendo Pharma is the company’s third since spinning out of Merck in the summer. Clinical-stage Forendo is developing a new, potentially more targeted approach to treating endometriosis.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
The FDA has approved Brexafemme, a Scynexis antifungal drug, for treating vaginal yeast infections. The drug is the biotech’s first FDA-approved product and it also represents the first new antifungal drug class in 20 years.
Apprentice, a Jersey City, New Jersey-based startup, has raised $2.5 million from Silverton Partners and Hemi Ventures to improve its augmented reality solution.
GE leads a $10 million round in a company that intends to make the management of hospital clinical and non-clinical capital equipment headache free and mobile enabled.
Late Friday, MT Pharma America broke the news that the FDA had approved its experimental amyotrophic lateral sclerosis (ALS) drug Radicava, the second-ever drug approved for ALS and the first in over 20 years.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.